Xingbo Cheng

913 total citations
25 papers, 556 citations indexed

About

Xingbo Cheng is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Xingbo Cheng has authored 25 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Epidemiology. Recurrent topics in Xingbo Cheng's work include Ferroptosis and cancer prognosis (6 papers), Adipokines, Inflammation, and Metabolic Diseases (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Xingbo Cheng is often cited by papers focused on Ferroptosis and cancer prognosis (6 papers), Adipokines, Inflammation, and Metabolic Diseases (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Xingbo Cheng collaborates with scholars based in China, United States and Canada. Xingbo Cheng's co-authors include Lei Zhang, Chao Chen, Fusong Jiang, Nan Zhou, Huaying Fan, Bei Zhu, Hong Xu, Wei Li, Ming‐Hua Zheng and Zhang Hui and has published in prestigious journals such as The International Journal of Biochemistry & Cell Biology, Clinica Chimica Acta and Journal of Cellular and Molecular Medicine.

In The Last Decade

Xingbo Cheng

23 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xingbo Cheng China 11 271 187 147 138 50 25 556
Katherine Tonks Australia 11 286 1.1× 246 1.3× 198 1.3× 164 1.2× 75 1.5× 24 668
Diego Fernández‐García Spain 12 163 0.6× 157 0.8× 126 0.9× 141 1.0× 79 1.6× 34 512
Sara Andrade Portugal 12 220 0.8× 172 0.9× 171 1.2× 101 0.7× 85 1.7× 34 619
Theodora Tzanavari Greece 7 235 0.9× 148 0.8× 249 1.7× 55 0.4× 40 0.8× 10 576
Emma Nilsson Denmark 11 338 1.2× 354 1.9× 146 1.0× 136 1.0× 88 1.8× 14 719
Titta Salopuro Finland 8 245 0.9× 114 0.6× 129 0.9× 131 0.9× 40 0.8× 11 495
Daniela Dietze‐Schroeder Germany 7 318 1.2× 153 0.8× 298 2.0× 71 0.5× 59 1.2× 7 537
T. Tatarczyk Austria 14 195 0.7× 154 0.8× 176 1.2× 108 0.8× 100 2.0× 21 594
Konstantinos Stefanakis United States 10 139 0.5× 83 0.4× 183 1.2× 116 0.8× 58 1.2× 20 401
Daniella Lent-Schochet United States 9 131 0.5× 136 0.7× 126 0.9× 98 0.7× 36 0.7× 17 470

Countries citing papers authored by Xingbo Cheng

Since Specialization
Citations

This map shows the geographic impact of Xingbo Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingbo Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingbo Cheng more than expected).

Fields of papers citing papers by Xingbo Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingbo Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingbo Cheng. The network helps show where Xingbo Cheng may publish in the future.

Co-authorship network of co-authors of Xingbo Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Xingbo Cheng. A scholar is included among the top collaborators of Xingbo Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingbo Cheng. Xingbo Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Xingbo, et al.. (2023). ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy. The International Journal of Biochemistry & Cell Biology. 158. 106409–106409. 4 indexed citations
2.
Fan, Huaying, et al.. (2023). Serum C1q/TNF-Related Protein 4 Levels are Associated with Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. Metabolic Syndrome and Related Disorders. 21(3). 163–168.
3.
Cheng, Xingbo, Pengxu Li, Zhaoyue Yan, et al.. (2022). CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis. Current Research in Translational Medicine. 70(4). 103345–103345. 2 indexed citations
4.
Zhang, Lei, et al.. (2021). Alteration of serum neuregulin 4 and neuregulin 1 in gestational diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism. 12. 2425418894–2425418894. 15 indexed citations
5.
Liu, Zhendong, Binfeng Liu, Hongbo Wang, et al.. (2021). ITGB3BP is a potential biomarker associated with poor prognosis of glioma. Journal of Cellular and Molecular Medicine. 26(3). 813–827. 3 indexed citations
6.
Li, Hu, Xingbo Cheng, Zev A. Binder, et al.. (2021). Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy. Frontiers in Oncology. 11. 640910–640910. 17 indexed citations
7.
Cheng, Xingbo, et al.. (2021). Expression and clinical significance of TIMELESS in glioma.. International Journal of Clinical and Experimental Pathology. 14(9). 938–955.
8.
Fan, Huaying, et al.. (2020). The relation between serum adipose differentiation-related protein and non-alcoholic fatty liver disease in type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism. 11. 2389889601–2389889601. 10 indexed citations
9.
Li, Tiantian, Min Sun, Yong Gu, et al.. (2019). A survey on the present status of diagnosis and treatment of Graves′ disease in Jiangsu province. Zhonghua neifenmi daixie zazhi. 35(7). 576–580. 1 indexed citations
10.
Pan, Xiaoyan, Yijing Han, Tiantian Zou, et al.. (2018). Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis. Digestive Diseases. 36(6). 427–436. 46 indexed citations
11.
12.
Xie, Jing, et al.. (2016). Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy. Diabetes Research and Clinical Practice. 115. 68–75. 27 indexed citations
13.
Ying, Changjiang, et al.. (2016). Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats. Endocrine. 53(1). 81–96. 35 indexed citations
14.
Ma, Jianhua, Jialin Gao, Wei Li, et al.. (2015). Clinical efficacy and safety of epalrestat in diabetic neuropathy—A multicenter randomized controlled clinical trial. Zhonghua neifenmi daixie zazhi. 31(9). 743–747. 2 indexed citations
15.
Lü, Yan, Yiqun Lu, Xingbo Cheng, Huijuan Li, & Yafeng Zhou. (2012). Significance of serum 8-Hydroxydeoxyguanosine levels to the intima-media thickness of the carotid artery in type 2 diabetes. Asian Biomedicine. 6(5). 759–764. 4 indexed citations
16.
Cheng, Xingbo, Yi‐Ting Hsieh, Shih‐Te Tu, & Ming‐Chia Hsieh. (2012). Obesity and low target attainment rates in Chinese with type 2 diabetes. European Journal of Internal Medicine. 23(4). e101–e105. 4 indexed citations
17.
Lu, Yiqun, Yan Lu, Huijuan Li, & Xingbo Cheng. (2012). Effect of advanced glycosylation end products (AGEs) on proliferation of human bone marrow mesenchymal stem cells (MSCs) in vitro. In Vitro Cellular & Developmental Biology - Animal. 48(9). 599–602. 10 indexed citations
18.
Cheng, Xingbo, Bei Zhu, Fusong Jiang, & Huaying Fan. (2011). Serum FGF-21 Levels in Type 2 Diabetic Patients. Endocrine Research. 36(4). 142–148. 62 indexed citations
19.
20.
Cheng, Xingbo & Zhang Hui. (2009). Serum retinal-binding protein 4 is positively related to insulin resistance in Chinese subjects with type 2 diabetes. Diabetes Research and Clinical Practice. 84(1). 58–60. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine Tonks Breakdown of academic impact, for papers by Diego Fernández‐García Breakdown of academic impact, for papers by Sara Andrade Breakdown of academic impact, for papers by Theodora Tzanavari Breakdown of academic impact, for papers by Emma Nilsson Breakdown of academic impact, for papers by Titta Salopuro Breakdown of academic impact, for papers by Daniela Dietze‐Schroeder Breakdown of academic impact, for papers by T. Tatarczyk Breakdown of academic impact, for papers by Konstantinos Stefanakis Breakdown of academic impact, for papers by Daniella Lent-Schochet
Rankless by CCL
2026